22236-1-AP

antibody from Proteintech Group

Targeting: BRD2 BRD2-IT1, D6S113E, FSRG1, KIAA9001, NAT, RING3

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Antibody Data

Product number

22236-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#22236-1-AP, RRID:AB_2722524

Product name

BRD2 antibody

Antibody type

Polyclonal

Description

BRD2 antibody (Cat. #22236-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IP, WB,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.

Morino S, Mashima T, Shirai F, Nagayama S, Katayama R, Seimiya H
Cancer letters 2024 Mar 1;584:216632

---

Mitochondrial Control of Proteasomal Psmb5 Drives the Differentiation of Tissue-Resident Memory T Cells in Patients with Rheumatoid Arthritis.

Wu T, Su D, Zhang L, Liu T, Wang Q, Yan C, Liu M, Ji H, Lei J, Zheng M, Wen Z
Arthritis & rheumatology (Hoboken, N.J.) 2024 Jul 22;

---

A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis.

Bao K, Ma Y, Li Y, Shen X, Zhao J, Tian S, Zhang C, Liang C, Zhao Z, Yang Y, Zhang K, Yang N, Meng FL, Hao J, Yang J, Liu T, Yao Z, Ai D, Shi L
Molecular cell 2024 Apr 4;84(7):1206-1223.e15

---

The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.

Zhu X, Liu W, Tang X, Chen Y, Ge X, Ke Q, Liang X, Gan Y, Zheng Y, Zou M, Deng M, Liu Y, Li DW, Gong L
Journal of neuroinflammation 2023 May 22;20(1):119

---

The H2A.Z and NuRD associated protein HMG20A controls early head and heart developmental transcription programs.

Herchenröther A, Gossen S, Friedrich T, Reim A, Daus N, Diegmüller F, Leers J, Sani HM, Gerstner S, Schwarz L, Stellmacher I, Szymkowiak LV, Nist A, Stiewe T, Borggrefe T, Mann M, Mackay JP, Bartkuhn M, Borchers A, Lan J, Hake SB
Nature communications 2023 Jan 28;14(1):472

---

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.

Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, Oguz G, Feng M, Lee PL, Li B, Yang ZH, Chen YF, Lan P, Wu XJ, Yu Q
Nature communications 2021 Jul 21;12(1):4441

---

The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.

Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J, Lin W
Frontiers in oncology 2020;10:565820

---

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W
Nature medicine 2017 Sep;23(9):1063-1071